The pCODR Expert Review Committee (pERC) has not recommended the funding of Zaltrap (aflibercept) when used in combination with an irinotecan-fluoropyrimidine (FOLFIRI) based therapy for patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.  The Committee made this decision because compared to placebo plus FOLFIRI, aflibercept plus FOLFIRI has only a modest overall survival and progression-free survival benefit, significant toxicity and an unknown impact on health related quality of life.  Additionally, the combination of aflibercept plus FOLFIRI was not cost-effective when compared to FOlFIRI alone.

For more details, go to: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-zaltrap-mcrc-fn-rec.pdf